At a glance
- Originator Novartis
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 13 Jun 2001 No-Development-Reported for Diabetes mellitus in USA (PO)
- 08 Dec 1997 Preclinical development for Diabetes mellitus in USA (PO)